Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
The five signals buyers underwrite before they discuss price
Behavioral health investors prioritize five signals: payer mix and in-network contract quality, licensure and accreditation posture (state license plus The Joint Commission or CARF International), census stability with documented length-of-stay and outcomes, a defensible compliance infrastructure spanning clinical, billing, and HR, and a scalable operating model with real EBITDA. Revenue growth without those five is a flag, not an asset.
The market context matters. Mertz Taggart counted 180 total behavioral health transactions in 2025, a modest increase from 176 in 2024. A flight-to-quality theme has emerged, where premium assets with strong outcomes and management still command high multiples, while distressed situations are increasingly common. Translation for operators: the gap between what a clean platform earns and what a messy one earns has widened dramatically.
Demand is not the question. Among adults aged 18 or older in 2023, 22.8% (or 58.7 million people) had any mental illness. Among the 48.5 million people aged 12 or older who had an SUD in 2023 and were therefore classified as needing substance use treatment, 15.6 percent (7.1 million people) received treatment and 85.4 percent (41.1 million people) did not. Buyers know the demand is there. They are underwriting whether you can capture it without blowing up a federal compliance issue.
Payer mix is the single biggest valuation lever
Sophisticated buyers model payer mix line by line before they ever send a letter of intent. A $3M EBITDA behavioral health practice with 70% commercial insurance trades at 12x+. The same EBITDA with 70% Medicaid trades at 7x. PE firms are buying insurance contracts, not just patient volume. That is not an abstraction. That is a $15 million swing on the same clinical operation.
What they want to see, in order:
- In-network single case agreements converted to full contracts. Out-of-network cash collections look great until the No Surprises Act and plan-level utilization management chews through them. Out-of-network SUD providers generally see multiples between 4X and 6X. In-network SUD and mental health providers can command higher multiples, often above 6X if they demonstrate strong operational efficiency.
- Payer contracts with real escalators and rate transparency. Buyers run their own MHPAEA (Mental Health Parity and Addiction Equity Act) exposure modeling now. If your commercial rates look inflated versus Medicaid NOMs for the same CPT, they will discount the forward rate.
- Clean Medicaid managed care participation. In Florida the DCF-licensed operators dealing with Sunshine Health and Simply, in Pennsylvania the DDAP-licensed providers working through HealthChoices BH-MCOs, in New Jersey the DMHAS-contracted sites running through Horizon NJ Health, each state’s MCO rate card gets pulled apart in diligence.
If your pro forma assumes commercial rates persist at 180% of Medicaid in perpetuity, expect the buyer to haircut it. KFF and CMS have both signaled sustained parity enforcement, and buyers are pricing it in.
Licensure and accreditation posture: the binder they ask for in week one
In the first ten business days of diligence, the buyer’s healthcare counsel will request a very specific stack of documents. Have them ready, or watch the deal timeline slip 60 days.
- Current state license and the last three surveys with every statement of deficiency and plan of correction. Florida DCF, Pennsylvania DDAP, New Jersey DMHAS, Texas HHSC, and Montana’s licensing boards all post or produce these on request. Buyers will pull them independently. If you did not disclose an uncorrected Class II deficiency, you have just damaged trust.
- Joint Commission or CARF accreditation certificate, survey report, and any ESC (Evidence of Standards Compliance) submissions. A one-year provisional accreditation is survivable in diligence. Hiding it is not.
- DEA registration for any OTP or office-based buprenorphine program, plus the SAMHSA certification for OTPs. If you prescribe controlled substances, DEA and SAMHSA compliance history is table stakes.
- ASAM Criteria 4th Edition level-of-care documentation. If you operate residential withdrawal management (ASAM Level 3.7 under the 4th edition), PHP at the 2.5 outpatient level, or IOP, buyers want to see admission criteria, continued stay reviews, and discharge documentation that actually matches the level billed.
Institutional capital does not require accreditation to take a meeting. Institutional capital requires accreditation to close at a premium multiple. Across all behavioral categories, 2025 multiples have remained stable compared to 2023-2024, with premium outcomes concentrated among scaled, multi-state platforms with accreditation, diversified payer relationships, and strong clinical governance.
The compliance red flags that kill LOIs in diligence
Competitor posts tell operators to clean up the cap table and the QuickBooks file. That is table stakes. The deals that actually die in diligence die on four regulatory issues, in roughly this order of frequency:
- EKRA exposure. The Eliminating Kickbacks in Recovery Act criminalizes percentage-of-collections marketing arrangements across all payer types, including commercial, not just federal programs. If your marketing agreements, call-center vendors, or outbound BDRs are paid on admissions or revenue percentages, a buyer’s counsel will flag it and demand indemnity escrow or walk.
- 42 CFR Part 2 breach history. SUD confidentiality rules are stricter than HIPAA. A single improperly disclosed treatment record, especially one disclosed to a Medicaid MCO or a referring court without proper consent, becomes a diligence line item. Document every consent, every release, every correction.
- Anti-Kickback Statute and Stark Law physician relationships. Medical director agreements that are not fair-market-value, not commercially reasonable, or not documented with time logs are the single most common AKS issue the OIG flags in behavioral health. The OIG has issued multiple advisory opinions on patient-brokering structures. Buyers read them.
- SIU audits and payer takeback exposure. If a commercial payer’s Special Investigations Unit has an open audit, buyers will reserve against it. We have seen holdbacks exceed 15% of enterprise value when SIU letters surface late in diligence.
As Mertz Taggart managing partner Kevin Taggart put it, “We are seeing a trend of fewer deal announcements. Private equity’s push into healthcare has been under public and regulatory scrutiny over the past 12 to 24 months.” Quieter deals mean cleaner diligence files. The operators who prepare for that scrutiny before they hire a banker get paid for it.
Frequently asked questions
What EBITDA multiple do behavioral health treatment centers trade at in 2024-2025?
It depends on sub-sector, scale, and payer mix. Capstone Partners reported outpatient SUD treatment groups at $10M+ adjusted EBITDA trading at 9.0x to 13.5x adjusted EBITDA in 2024-2025, with outpatient mental health platforms at $10M+ adjusted EBITDA reported at 8.5x to 12.5x adjusted EBITDA. At the sub-$3M adjusted EBITDA tier, behavioral health group practices have been reported at 5.5x to 9.0x adjusted EBITDA. Residential SUD, especially out-of-network, trades meaningfully lower.
How much revenue do I need before PE will take a meeting?
Platform conversations typically start around $3M of normalized EBITDA. Below that, you are an add-on candidate for an existing platform, not a standalone acquisition. Growth-equity rounds for tech-enabled behavioral health will take meetings earlier if the unit economics are proven.
Does payer mix really affect valuation, and by how much?
Yes, materially. The same $3M EBITDA business can trade at 7x with heavy Medicaid or 12x+ with heavy commercial in-network. That is a $15M swing on identical clinical operations.
What compliance red flags will kill a deal in diligence?
EKRA-violating marketing agreements, undisclosed 42 CFR Part 2 breaches, non-FMV medical director relationships that implicate the Anti-Kickback Statute, open SIU audits with meaningful takeback exposure, and uncorrected state licensure deficiencies. Any one of these can trigger a repricing, an escrow, or a walk.
Is Joint Commission or CARF accreditation required to attract institutional capital?
Not required to take a meeting. Effectively required to close at a premium multiple, especially for commercial in-network platforms. Most sophisticated commercial payers now require TJC or CARF for in-network contracting, which means accreditation is upstream of the payer mix the buyer is actually underwriting.
References
- Mertz Taggart, Q4 2025 Behavioral Health M&A Report
- Behavioral Health Business, Behavioral Health Dealmaking Dips to Pre-Pandemic Levels (August 2025)
- FOCUS Investment Banking, Behavioral Health EBITDA Multiples: 2025 Update
- FOCUS Investment Banking, Healthcare EBITDA Multiples: 2026 Dashboard
- Healthcare Services M&A Multiples Report 2026 (citing Capstone Partners Behavioral Health M&A)
- SAMHSA, Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 NSDUH
- NACo summary of SAMHSA 2023 NSDUH treatment gap data
- U.S. Department of Justice, Eliminating Kickbacks in Recovery Act (EKRA) overview